Claim Missing Document
Check
Articles

Found 12 Documents
Search

Effectiveness of Honey Soy Milk on Hemoglobin Improvement among Adolescent Girls with Menstrual Anemia: A Quasi-Experimental Study Yuniza, Yuniza; Ginanjar, Marwan Riki; Ulaa, Mar’atun; Williams, Brett
Journal of Applied Nursing and Health Vol. 8 No. 1 (2026): Journal of Applied Nursing and Health
Publisher : Chakra Brahmanda Lentera Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55018/janh.v8i1.430

Abstract

Background: Anemia is a common health problem among adolescent girls, primarily due to iron deficiency and blood loss during menstruation. Honey contains bioactive compounds beneficial to health, including the improvement of metabolism and hematological status. This study aims to determine the effect of honey soy milk on hemoglobin (Hb) levels among adolescent girls with menstrual anemia. Methods: This quantitative study employed a quasi-experimental design with one group pretest–posttest, conducted at an educational institution in Indonesia. A total of 25 adolescent girls with menstrual anemia were selected using purposive sampling based on inclusion and exclusion criteria. The intervention consisted of administering 200 mL of honey soy milk twice daily for 5 consecutive days during menstruation. Hemoglobin levels were measured in g/dL using an EasyTouch GCHb digital analyzer before and after the intervention. Data analysis followed the Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) guidelines. Results: The mean hemoglobin level before the intervention was 11.15 ± 1.72 g/dL, and after the intervention, it increased to 12.92 ± 1.87 g/dL. Statistical testing showed a significant difference (p < 0.001), indicating that honey soy milk effectively improved Hb levels among participants. Conclusion: Honey soy milk is effective in increasing hemoglobin levels in adolescent girls with menstrual anemia. These findings support the use of functional foods as an adjunctive strategy in anemia prevention and management programs for adolescents
Efektivitas Penambahan Suplementasi Vitamin C Terhadap Penurunan Malondialdehid dan Perbaikan Derajat Aktivitas Penyakit Lupus Eritematosus Sistemik: Uji Klinis Acak Tersamar Ganda Yuniza, Yuniza; Kurniati, Nova; Theodorus, Theodorus; Salim, Eddy M; Hartanto, Kristian S
Jurnal Penyakit Dalam Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Vitamin C is an antioxidant that exerts its effects at multiple cellular levels. However, evidence regarding its effects in systemic lupus erythematosus (SLE) remain inconclusive. This study aimed to evaluate the potential of vitamin as an adjunctive antioxidant therapy in patients with SLE by assessing its effects on serum malondialdehyde (MDA) levels and disease activity using the Mexical Systemic Lupus Erythematosus Disease Activity Index (MEX-SLEDAI) score. Methods. This pilot double-blind, randomized controlled trial was conducted at Dr. Mohammad Hoesin General Hospital, Palembang. Participants were patients with mild-to-moderate SLE diagnosed according to the 2019 European Alliance of Association for Rheumatology/American College of Rheumatology (EULAR/ACR) classification criteria and assessed using the MEX-SLEDAI score. Subjects were randomly assigned to receive either vitamin C (500 mg twice dailiy for 2 months) or placebo in addition to standard SLE therapy. Serum MDA levels and MEX-SLEDAI scores were measured at baseline and after the intervention. Results. A total of 34 subjects were enrolled in the study. The mean baseline serum MDA concentration was 1.38 (SD 0.31) μmol/L. After 2 months of treatment, the vitamin C group demonstrated a significant reduction in serum MDA levels [1.38 (SD 0.38) μmol/L vs. 1.09 (SD 0.26) μmol/L; p = 0.003] and MEX-SLEDAI scores [median 2 (2–5) vs. 1 (0–2); p = 0.001]. In the placebo group, only the MEX-SLEDAI score decreased significantly [3 (2–7) vs. 2 (0–6); p = 0.016], whereas serum MDA levels showed no significant change [1.37 (SD 0.25) μmol/L vs. 1.32 (SD 0.38) μmol/L; p = 0.518]. Between-group comparisons revealed that both the reduction in MDA (p = 0.047) and MEX-SLEDAI (p=0.048) were significantly greater in the vitamin C group compared to placebo group. Conclusions. Vitamin C supplementation at dose of 500 mg twice daily as an adjuct to standard therapy could reduce disease activity and serum MDA levels in patients with mild-to-moderate SLE.